MX2009004775A - Nuevos compuestos y metodos para su produccion. - Google Patents
Nuevos compuestos y metodos para su produccion.Info
- Publication number
- MX2009004775A MX2009004775A MX2009004775A MX2009004775A MX2009004775A MX 2009004775 A MX2009004775 A MX 2009004775A MX 2009004775 A MX2009004775 A MX 2009004775A MX 2009004775 A MX2009004775 A MX 2009004775A MX 2009004775 A MX2009004775 A MX 2009004775A
- Authority
- MX
- Mexico
- Prior art keywords
- production
- diseases
- methods
- novel compounds
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a análogos de ansamicina que son útiles, por ejemplo en el tratamiento de cáncer, malignidades de la célula B, paludismo, infección por hongos, enfermedad del sistema nervioso central y enfermedades neurodegenerativas, enfermedades dependientes de angiogénesis, enfermedades autoinmunitarias o un pretratamiento profiláctico para cáncer. La presente invención también proporciona métodos para la producción de estos compuestos y su uso en medicina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0622342.4A GB0622342D0 (en) | 2006-11-09 | 2006-11-09 | Novel compounds and methods for their production |
GB0720875A GB0720875D0 (en) | 2007-10-24 | 2007-10-24 | Novel compounds and methods for their production |
PCT/GB2007/050679 WO2008056188A2 (en) | 2006-11-09 | 2007-11-09 | Novel compounds and methods for their production |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004775A true MX2009004775A (es) | 2009-05-21 |
Family
ID=39362724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004775A MX2009004775A (es) | 2006-11-09 | 2007-11-09 | Nuevos compuestos y metodos para su produccion. |
Country Status (10)
Country | Link |
---|---|
US (1) | US8492370B2 (es) |
EP (1) | EP1973883B1 (es) |
JP (1) | JP2010509306A (es) |
KR (1) | KR20090075856A (es) |
AU (1) | AU2007319014B2 (es) |
BR (1) | BRPI0718564A2 (es) |
CA (1) | CA2669047A1 (es) |
ES (1) | ES2389740T3 (es) |
MX (1) | MX2009004775A (es) |
WO (1) | WO2008056188A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008094438A1 (en) | 2007-01-26 | 2008-08-07 | Kosan Biosciences Incorporated | Macrolactams by engineered biosynthesis |
KR101097850B1 (ko) | 2009-02-24 | 2011-12-23 | 한국생명공학연구원 | 젤다나마이신 생합성 조절유전자 변이주 및 이를 이용한 젤다나마이신 생산방법 |
CN117695374B (zh) * | 2024-01-25 | 2024-09-06 | 超越健康科技(浙江)有限公司 | 一种用于治疗帕金森病的生物药物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06510913A (ja) * | 1992-01-06 | 1994-12-08 | フアイザー・インコーポレイテツド | 4,5‐ジヒドロゲルダナマイシン及びそのヒドロキノンの製造及び使用 |
AU2003217393B8 (en) * | 2002-02-08 | 2009-06-25 | Conforma Therapeutics Corporation | Ansamycins having improved pharmacological and biological properties |
ES2409351T3 (es) | 2003-12-23 | 2013-06-26 | Infinity Discovery, Inc. | Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer |
JPWO2005061461A1 (ja) * | 2003-12-24 | 2007-07-12 | 協和醗酵工業株式会社 | ヒートショックプロテイン90(hsp90)ファミリー蛋白質阻害剤 |
US7608611B2 (en) * | 2005-03-11 | 2009-10-27 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
WO2007001049A1 (ja) * | 2005-06-29 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | ベンゼノイドアンサマイシン誘導体 |
US20090209494A1 (en) | 2005-12-24 | 2009-08-20 | Christine Janet Martin | 21-deoxymacbecin analogues useful as antitumor agents |
CN101012196A (zh) * | 2006-12-27 | 2007-08-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳香化格尔德霉素类衍生物及其制备方法和用途 |
WO2008094438A1 (en) * | 2007-01-26 | 2008-08-07 | Kosan Biosciences Incorporated | Macrolactams by engineered biosynthesis |
-
2007
- 2007-11-09 JP JP2009535815A patent/JP2010509306A/ja active Pending
- 2007-11-09 US US12/513,967 patent/US8492370B2/en active Active
- 2007-11-09 AU AU2007319014A patent/AU2007319014B2/en not_active Ceased
- 2007-11-09 CA CA002669047A patent/CA2669047A1/en not_active Abandoned
- 2007-11-09 KR KR1020097009593A patent/KR20090075856A/ko not_active Application Discontinuation
- 2007-11-09 BR BRPI0718564-2A patent/BRPI0718564A2/pt not_active IP Right Cessation
- 2007-11-09 WO PCT/GB2007/050679 patent/WO2008056188A2/en active Application Filing
- 2007-11-09 MX MX2009004775A patent/MX2009004775A/es active IP Right Grant
- 2007-11-09 EP EP07824891A patent/EP1973883B1/en not_active Not-in-force
- 2007-11-09 ES ES07824891T patent/ES2389740T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
ES2389740T3 (es) | 2012-10-31 |
US8492370B2 (en) | 2013-07-23 |
AU2007319014A1 (en) | 2008-05-15 |
BRPI0718564A2 (pt) | 2014-03-11 |
US20110021481A1 (en) | 2011-01-27 |
EP1973883B1 (en) | 2012-07-11 |
AU2007319014B2 (en) | 2013-03-28 |
EP1973883A2 (en) | 2008-10-01 |
WO2008056188A2 (en) | 2008-05-15 |
KR20090075856A (ko) | 2009-07-09 |
CA2669047A1 (en) | 2008-05-15 |
WO2008056188A3 (en) | 2008-07-31 |
JP2010509306A (ja) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO2858B1 (en) | Pharmaceutical dosage images | |
TW200800968A (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
UA108198C2 (uk) | Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування | |
HK1139930A1 (en) | Cyclopamine lactam analogs and methods of use thereof | |
PT2069324E (pt) | Amino piridina fundida como inibidor da hsp90 | |
UA102065C2 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
NZ708727A (en) | Conjugate compounds | |
TW200508201A (en) | Novel process for the preparation of roflumilast | |
UA107448C2 (uk) | Ліпохітоолігосахариди, що стимулюють арбускулярно-мікоризний симбіоз | |
MX2011011342A (es) | Compuestos de vinil indazolilo. | |
TN2012000108A1 (en) | Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs | |
WO2008136976A3 (en) | Compounds for treating proliferative disorders | |
WO2008095086A3 (en) | Topiramate plus naltrexone for the treatment of addictive disorders | |
WO2008024302A8 (en) | Compounds for treating proliferative disorders | |
TN2011000647A1 (en) | Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria | |
GEP20115293B (en) | Isolated extract of walnuts, process for its obtaining and its use | |
MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. | |
AU2013212209A8 (en) | (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof | |
WO2007128829A3 (en) | 18,21-didesoxymacbecin derivatives for the treatment of cancer | |
MX2009004775A (es) | Nuevos compuestos y metodos para su produccion. | |
MY149864A (en) | Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |